Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma (Oncotarget (2018) 9 (31264-31277) DOI: 10.18632/oncotarget.25805)

Michal Alon, Rand Arafeh, Joo Sang Lee, Sanna Madan, Shelly Kalaora, Adi Nagler, Tereza Abgarian, Polina Greenberg, Eytan Ruppin, Yardena Samuels

Research output: Contribution to journalComment/debate

Abstract

This article has been corrected: The correct Acknowledgments information is given below: ACKNOWLEDGMENTS The authors thank Tamar Ziv and Arie Admon (The Smoler Proteomics Center, Technion, Israel) for the proteomic analysis. The authors also thank Antonella Di Pizio and Masha Y. Niv (The Hebrew University of Jerusalem, Israel) for performing the structural analysis on predicted NF1 cleavage sites. The authors also thank The De Botton Protein Profiling institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science for identifying the proteolytic product of NF1. The work was supported by Minerva Foundation Grant.

Original languageEnglish
Pages (from-to)1344
Number of pages1
JournalOncotarget
Volume10
Issue number13
StatePublished - 1 Feb 2019
Externally publishedYes

Fingerprint

Dive into the research topics of 'Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma (Oncotarget (2018) 9 (31264-31277) DOI: 10.18632/oncotarget.25805)'. Together they form a unique fingerprint.

Cite this